Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a 'smart' stem cell transplant free patients from a lifetime of anti-rejection drugs?

NCT ID NCT04678401

Recruiting now Disease control Sponsor: Dana-Farber Cancer Institute Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study tests a new stem cell transplant method for people with aggressive or hard-to-treat acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS). The approach uses specially engineered donor cells to reduce the risk of graft-versus-host disease, potentially allowing patients to avoid lifelong immunosuppressive drugs. Up to 30 participants will receive radiation, chemotherapy, and an infusion of regulatory T-cell enriched donor stem cells.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Regulatory T-cell enriched donor stem cells
What this could lead to
If successful, this approach could allow patients with aggressive leukemia or MDS to receive a stem cell transplant without needing lifelong anti-rejection drugs.
What could go wrong
This is a very early phase 1 trial with only 30 participants, so safety and effectiveness are not yet proven. There are risks of graft failure, severe infection, or graft-versus-host disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GRAFT VS HOST DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia disease related to hematopoietic stem cell transplant graft versus host disease myelodysplastic syndrome Myelodysplastic Syndromes myeloid leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GRAFT VS HOST DISEASE MYELODYSPLASTIC SYNDROMES MYELOID LEUKEMIA IN RELAPSE (DISORDER) MYELOID LEUKEMIA, ACUTE STEM CELL TRANSPLANT COMPLICATIONS

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Dana Farber Cancer Institute

    RECRUITING

    Boston, Massachusetts, 02115, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

More trials for these conditions

Other studies related to the condition(s) this trial covers.